CLOV Company Profile and Key Details

CLOV has shown mixed momentum, gaining 7.66% over the past week and -6.3% over the past quarter, though year-to-date performance is up 7.66%. Short-term trend indicators are bullishly aligned (SMA20 1.82%, SMA50 -1.24%, SMA200 -12.07%). The stock’s 14-day RSI is 52.82 (neutral), while the ATR of 0.12 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -46.61% below its high and over 22.64% above its low. Average 10-day trading volume of 4.89 million shares is below the 3-month average of 6.95 million, indicating normal recent market interest.

Clover Health Investments, Corp. generated EPS of -$0.12 over the past year. Five-year average earnings growth is -237.67%. The latest quarter delivered EPS of $0.00. The next quarter is forecast at -$0.10. Next year's EPS is expected at $54.26. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $4.50 to $3.00. The high target offers 73.08% upside. The low target suggests 15.38% downside. The mean target is $3.83. This offers 47.31% upside. Clover Health Investments, Corp. earnings surprise history is a mixed track record. The quarter that ended November 04, 2025, missed forecasts by -95.65%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include 120.26% in August 05, 2024.

Clover Health Investments, Corp. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$3.37. This means the shares are trading below this model’s fair value.

Clover Health Investments, Corp. has 420.14 million shares outstanding. The public float is 400.29 million shares, elevated short interest at 12.30% of float. This equals 50.28 million shares. The short ratio is 5.16 days. Institutional investors hold 36.69% of the float. Insiders own 3.88%. Reynoso Jamie L. holds 2.76 million shares, Priest Brady Patrick has 2.42 million shares and Garipalli Vivek has 1.86 million shares. Over the past six months, insider transactions show net selling. They sold 277.46 thousand shares across 9 transactions.

Clover Health Investments, Corp. (NASDAQ:CLOV) closed at $2.60 USD, gaining $0.07 (2.77%) from the previous close of $2.53. The stock is currently mid-range between its 52-week high and low $2.12 and $4.87. With a market capitalization of about $1.34 billion, Clover Health Investments, Corp. is classified as a small-cap and shows higher-than-market volatility (beta ~2.13). Key stats such as the average daily volume over the past year has been around 6.97 million shares, volume is running light vs its 52-week average. Headquartered in Franklin, TN, Clover Health Investments, Corp. operates in the Healthcare sector and the Medical - Healthcare Plans industry. Led by CEO Andrew Toy, the company employs approximately 570 people and listed since June 12, 2020. Clover Health Investments, Corp. operates as a medicare advantage insurer in the United States.

Clover Health Investments, Corp. (NASDAQ:CLOV) shares are flat 7.66% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Clover Health Investments, Corp. trading at a premium to the broader market with a P/E of -22.86. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $6.20, suggesting 138.46% upside. Our AI forecast model points to short-term weakness (-5.38% over two weeks), a medium-term fall (-21.15% over three months), and a longer-term gain (275.38% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Clover Health Investments, Corp. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.38%, with price expected at $2.46 by January 23, 2026, within a range of $2.37 to $2.56 3-Month Outlook: Projected fall of -21.15%, reaching $2.05 by April 09, 2026, with a range of $1.90 to $2.18. 1-Year Outlook: Projected gain of 275.38%, with price at $9.76 by December 31, 2026, within a range of $9.69 to $9.86.

Clover Health Investments, Corp. trades at a P/E ratio of -22.86, slightly below the S&P 500 average, with a price-to-sales ratio of 0.76 and a price-to-book ratio of 3.91 trading at moderately above to book value. The P/FCF stands at -15.54, also below market averages.